Drug Trial Radar · NCT04987229
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
236
Planned (sponsor's estimate)
Start
Oct 22, 2021
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Alkermes, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder
Conditions
- Bipolar I Disorder
- Schizophrenia
Interventions
OLZ/SAMDrug
Olanzapine and Samidorphan fixed dose coated tablet taken once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Up to 52 weeks
Locations
35 sites in 5 countries. Site status is shown where the registry gives one.
Alkermes Investigational Site
Dothan, Alabama
Alkermes Investigational Site
Little Rock, Arkansas
Alkermes Investigational Site
Stanford, California
Alkermes Investigational Site
Washington D.C., District of Columbia
Alkermes Investigational Site
Miami Lakes, Florida
Alkermes Investigational Site
Decatur, Georgia
Alkermes Investigational Site
Chicago, Illinois
Alkermes Investigational Site
Indianapolis, Indiana
Alkermes Investigational Site
Saint Charles, Missouri
Alkermes Investigational Site
Lincoln, Nebraska
Alkermes Investigator Site
New York, New York
Alkermes Investigational Site
Cincinnati, Ohio
Alkermes Investigational Site
West Chester, Ohio
Alkermes Investigational Site
Richmond, Virginia
Alkermes Investigational Site
Everett, Washington
Alkermes Investigational Site
Córdoba, Argentina
Alkermes Investigational Site
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Alkermes Investigational Site
La Plata, Buenos Aires, Argentina
Alkermes Investigational Site
Buenos Aires, Buenos Aires F.D., Argentina
Alkermes Investigational Site
Mendoza, Mendoza Province, Argentina
Alkermes Investigational Site
Goiânia, Brazil
Alkermes Investigational Site
São Paulo, Brazil
Alkermes Investigational Site
Fortaleza, Ceará, Brazil
Alkermes Investigational Site
Curitiba, Paraná, Brazil
Alkermes Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Alkermes Investigational Site
São Paulo, São Paulo, Brazil
Alkermes Investigational Site
Barranquilla, Colombia
Alkermes Investigational Site
Bello, Colombia
Alkermes Investigational Site
Bogotá, Colombia
Alkermes Investigational Site
Pereira, Colombia
Alkermes Investigational Site
León, Guanajuato, Mexico
Alkermes Investigational Site
Monterrey, Nuevo León, Mexico
Alkermes Investigational Site
Monterrey, Nuevo León, Mexico
Alkermes Investigational Site
Culiacán, Sinaloa, Mexico
Alkermes Investigational Site
Gustavo A. Madero, State of Mexico, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.